{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:04:48Z","timestamp":1780441488265,"version":"3.54.1"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPGN rep."],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec><jats:title>Objectives:<\/jats:title><jats:p>Vedolizumab is an anti\u2010\u03b14\u03b27 integrin antibody that has been used successfully in the treatment of adult\u2010onset inflammatory bowel diseases (IBDs: Crohn disease [CD] and ulcerative colitis [UC]). Its off\u2010label use in the pediatric IBD (PIBD) population is increasing, but knowledge on durability beyond 6 months of treatment is limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A real\u2010life, single\u2010center, retrospective study of PIBD patients treated with vedolizumab was performed. Data on demographics, prior and concomitant treatments, and disease activity were obtained at 14 weeks, 26 weeks, 1 year, and 2 years of therapy. Primary outcome was corticosteroid\u2010 and other biologic\u2010free remission (based on pediatric ulcerative colitis activity index [PUCAI]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Thirty\u2010nine patients were studied. By 1 year, 65% of CD and 68% of UC patients continued on vedolizumab therapy. Corticosteroid\u2010 and other biologic\u2010free remission was 29% in CD and 16% in UC. By 2 years, 36% of CD and 47% of UC patients continued therapy. Corticosteroid\u2010 and other biologic\u2010free remission was 21% in CD and 40% in UC. By 2 years, 80% of CD and 100% of UC patients were on intensified treatment regimen compared to the manufacturer guidance. Nine patients (23%) required surgical intervention within 26 months of starting vedolizumab indicating the severity of IBD in this cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Vedolizumab is a useful therapeutic modality in PIBD patients refractory to anti\u2010TNF therapy, although with declining effectiveness by 2 years. Intensified treatment regimens are associated with long\u2010term durability. Larger prospective trials in children are warranted.<\/jats:p><\/jats:sec>","DOI":"10.1097\/pg9.0000000000000276","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T21:00:07Z","timestamp":1672174807000},"source":"Crossref","is-referenced-by-count":5,"title":["A Single\u2010Center Study of Long\u2010Term Effectiveness of Vedolizumab in Anti\u2010TNF Refractory Pediatric Inflammatory Bowel Disease"],"prefix":"10.1002","volume":"4","author":[{"given":"Halee","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Pediatrics Section of Gastroenterology, Hepatology and Nutrition Baylor College of Medicine\/Texas Children's Hospital Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Karam","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Section of Gastroenterology, Hepatology and Nutrition Baylor College of Medicine\/Texas Children's Hospital Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kellermayer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Section of Gastroenterology, Hepatology and Nutrition Baylor College of Medicine\/Texas Children's Hospital Houston TX"},{"name":"Children's Nutrition and Research Center Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.sempedsurg.2017.10.010"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32448-0"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i25.2741"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-018-2665-5"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001050"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2020.01.054"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx143"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000865"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.07.007"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000918"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx082"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-018-0868-x"},{"key":"e_1_2_8_16_1","first-page":"1","article-title":"Vedolizumab experience in children and adolescents with inflammatory bowel disease: a multicenter observational study","volume":"3","author":"Hajjat TM","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac036"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz006"},{"key":"e_1_2_8_19_1","first-page":"423","article-title":"Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study","volume":"133","author":"Turner D","year":"2007","journal-title":"J Gastroenterol"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx125"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-020-03750-0"},{"key":"e_1_2_8_22_1","first-page":"616","article-title":"Efficacy and safety of adalimumab in paediatric patients with moderate\u2010to\u2010severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study","volume":"6","author":"Croft NM","year":"2021","journal-title":"Lancet"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22673.1"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-018-0623-z"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756284818772786"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002833"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001531"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy363"}],"container-title":["JPGN Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/PG9.0000000000000276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T14:45:14Z","timestamp":1749739514000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1097\/PG9.0000000000000276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1097\/PG9.0000000000000276"],"URL":"https:\/\/doi.org\/10.1097\/pg9.0000000000000276","archive":["Portico"],"relation":{},"ISSN":["2691-171X","2691-171X"],"issn-type":[{"value":"2691-171X","type":"print"},{"value":"2691-171X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]},"article-number":"e276"}}